drugset / Trial / NCT01069575

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer

NCT01069575

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of HLA-A\*2402 restricted epitope peptides URLC10, CDCA1, and KIF20A emulsified with Montanide ISA 51 for advanced non-small cell lung cancers.

Timeline

Start
2010-02
Primary completion
2019-03
Completion
2019-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CDCA1 Peptide 1 mg Subcutaneous
Subject CDCA1 Peptide 2 mg Subcutaneous
Subject CDCA1 Peptide 3 mg Subcutaneous
Subject KIF20A Peptide 1 mg Subcutaneous
Subject KIF20A Peptide 2 mg Subcutaneous
Subject KIF20A Peptide 3 mg Subcutaneous
Subject URLC10 Peptide 1 mg Subcutaneous
Subject URLC10 Peptide 2 mg Subcutaneous
Subject URLC10 Peptide 3 mg Subcutaneous